放射外科治疗符合ARUBA入组标准的动静脉畸形的获益:在适当随访期内的实用分析
该研究回顾性分析了1987至2016年间接受立体定向放射外科(SRS)治疗的符合ARUBA标准的未破裂脑动静脉畸形(AVM)患者,纳入至少随访3年或于潜伏期内发生卒中/死亡者。平均随访8.4年,卒中/死亡率为14%,显著低于ARUBA研究中未治疗队列按8.4年推算的30%(p=0.0003)。作者结论认为,在超过潜伏期的适当随访后,SRS治疗的未破裂AVM患者卒中/死亡发生率低于未治疗患者。
要点
- 平均随访8.4年,SRS治疗后卒中/死亡率为14%,显著低于ARUBA未治疗队列推算的30%(p=0.0003)。
- SRS后3年起,年化出血率为0.4%,年化卒中/死亡率为0.8%。
- 总体闭塞率为72%,新发癫痫、暂时性新发局灶缺损无卒中、永久性新发局灶缺损无卒中各占2%。
核心结论
- 在超过潜伏期的适当随访期后,接受SRS治疗的未破裂AVM患者卒中/死亡发生率低于未治疗患者。
研究设计与样本
- 回顾性分析本机构1987年至2016年间接受SRS治疗的符合ARUBA标准的AVM患者经验。
- 纳入至少随访3年的患者以及潜伏期内发生卒中或死亡的患者,主要结局为卒中(缺血性或出血性)或死亡(AVM相关或非相关)。
主要发现
- 共纳入233例患者,平均随访8.4年,32例(14%)在SRS后发生卒中或死亡。
- 利用ARUBA中未治疗AVM平均2.8年随访10%的卒中/死亡率推算,本研究8.4年随访的14%显著低于未治疗队列预期的30%(p=0.0003)。
- SRS后3年起,年化出血率为0.4%,年化卒中/死亡率为0.8%。
- 总体闭塞率为72%;新发癫痫、暂时性新发局灶缺损无卒中、永久性新发局灶缺损无卒中各占2%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE The authors of this study found that, given the latency period required for arteriovenous malformation (AVM) obliteration after stereotactic radiosurgery (SRS), a study with limited follow-up cannot assess the benefit of SRS for unruptured AVMs. METHODS The authors reviewed their institutional experience with "ARUBA (A Randomized Trial of Unruptured Brain Arteriovenous Malformations)-eligible" AVMs treated with SRS between 1987 and 2016, with the primary outcome defined as stroke (ischemic or hemorrhagic) or death (AVM related or AVM unrelated). Patients with at least 3 years of follow-up in addition to those who experienced stroke or died during the latency period were included. Secondary outcome measures included obliteration rates, patients with new seizure disorders, and those with new focal deficits without stroke. RESULTS Of 233 patients included in this study, 32 had a stroke or died after SRS over the mean 8.4-year follow-up (14%). Utilizing the 10% stroke or death rate at a mean 2.8-year follow-up for untreated AVMs in ARUBA, the rate in the authors' study is significantly lower than that anticipated at the 8.4-year follow-up for an untreated cohort (14% vs 30%, p = 0.0003). Notwithstanding obliteration, in this study, annualized rates of hemorrhage and stroke or death after 3 years following SRS were 0.4% and 0.8%, respectively. The overall obliteration rate was 72%; new seizure disorders, temporary new focal deficits without stroke, and permanent new focal deficits without stroke occurred in 2% of patients each. CONCLUSIONS After a sensible follow-up period exceeding the latency period, there is a lower rate of stroke/death for patients with treated, unruptured AVMs with SRS than for patients with untreated AVMs.
引用
- Tonetti DA, Gross BA, Atcheson KM, et al. The benefit of radiosurgery for ARUBA-eligible arteriovenous malformations: a practical analysis over an appropriate follow-up period. J Neurosurg. 2017. PMID: 28665253. doi:10.3171/2017.1.JNS162962
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。